Molecular determinants of AcrB-mediated bacterial efflux implications for drug discovery.
Department of Chemistry, Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States. john.manchester@astrazeneca.com
John I
JI
Manchester
Ed T
ET
Buurman
Gregory S
GS
Bisacchi
Robert E
RE
McLaughlin
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000235:genetics / Q000502:physiology*; D055808:Drug Discovery; D024881:Drug Resistance, Bacterial; D055786:Gene Knockout Techniques; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000235:genetics; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006193:Haemophilus influenzae / Q000187:drug effects / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics / Q000502:physiology*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins